Streetbeat News

HYPR

Hyperfine, Inc.

https://hyperfine.io

Industry

Medical - Devices

Hyperfine, Inc. provides imaging, monitoring, and magnetic resonance imaging products. It offers Swoop Portable MR imaging system to address an unmet need in point-of-care medical imaging through a combination of hardware and software services. The company was incorporated in 2014 and is based in Guilford, Connecticut.

Open

0.90

Mkt cap

71M

Volume

220K

High

1.00

P/E Ratio

-1.71

52-wk high

1.42

Low

0.88

Div yield

N/A

52-wk low

0.76

Hyperfine (NASDAQ:HYPR) has received FDA clearance for the ninth generation of its AI-powered Swoop® system software, which significantly reduces scan times for brain imaging without compromising quality. This positions Hyperfine as a leader in AI-powered health technology and could expedite diagnostics in acute care settings.

Portfolio Pulse from Benzinga Newsdesk

July 17, 2024 | 1:20 pm

Hyperfine's portable MRI system, Swoop®, shows promise in aiding critical stroke treatment decisions, according to a multi-site study published in the August 2024 edition of Annals of Neurology. The study provides early evidence from the ACTION PMR stroke study.

Portfolio Pulse from Benzinga Newsdesk

July 15, 2024 | 1:06 pm

Hyperfine, Inc. (NASDAQ:HYPR) will present clinical research on its Swoop® system for Alzheimer's disease monitoring at the 2024 Alzheimer's Association International Conference. The presentations will highlight the utility of portable ultra-low-field MRI in Alzheimer's care.

Portfolio Pulse from Benzinga Newsdesk

June 25, 2024 | 1:04 pm

Hyperfine, Inc. (NASDAQ:HYPR) has entered a distribution agreement with Radiosurgery Global, Ltd. to bring its portable MR brain imaging system, the Swoop®, to India. This strategic move aims to tap into the underserved MRI market in India and potentially expand to Malaysia, Indonesia, and Singapore.

Portfolio Pulse from Benzinga Newsdesk

May 28, 2024 | 1:01 pm

Hyperfine projects its FY24 revenue to be between $12M-$15M, aligning closely with the estimated $12.787M. The company anticipates a cash burn of around $40 million for the same period.

Portfolio Pulse from Benzinga Newsdesk

May 13, 2024 | 8:59 pm

Hyperfine (NASDAQ:HYPR) reported Q1 2024 earnings with a smaller loss per share of $(0.14) compared to the expected $(0.15), and sales of $3.295M, surpassing the $3.053M estimate. This represents a significant improvement over the previous year's performance.

Portfolio Pulse from Benzinga Newsdesk

May 13, 2024 | 8:50 pm

Hyperfine has entered into agreements with distributors in France, the UK, and Italy to expand its market presence in Europe. This strategic move aims to enhance the company's distribution network and increase access to its innovative medical imaging technology in these key European markets.

Portfolio Pulse from Benzinga Newsdesk

May 10, 2024 | 1:02 pm

Hyperfine announced that seventeen of its ultra-low-field MRI-related abstracts have been accepted for presentation at the 2024 International Society for Magnetic Resonance in Medicine Annual Meeting in Singapore. This acceptance highlights the company's innovative contributions to the field of magnetic resonance imaging.

Portfolio Pulse from Benzinga Newsdesk

April 23, 2024 | 1:06 pm

In Thursday's after-market session, several healthcare stocks showed significant movement. Biolase, Terns Pharma, Aptevo Therapeutics, Nexalin Technology, Evolus, and Phio Pharma were among the gainers, with Biolase leading by a 20% increase following their Q4 earnings release. On the downside, Cutera, Hyperfine, China SXT Pharmaceuticals, Vicarious Surgical, Meihua Intl Medical Techs, and Assure Holdings experienced declines, with Cutera dropping 11.7% after their Q4 earnings announcement.

Portfolio Pulse from Benzinga Insights

March 21, 2024 | 9:33 pm

Hyperfine (NASDAQ:HYPR) reported Q4 earnings with an EPS of $-0.15, beating estimates by 17.0% against an expected $-0.18. Revenue increased by $1.26 million year-over-year. Despite beating last quarter's EPS estimate, the share price dropped by 21.0% the following day. Historical earnings show mixed performance with both beats and misses on EPS and revenue estimates.

Portfolio Pulse from Benzinga Insights

March 21, 2024 | 8:10 pm

All corporate logos and prices are for illustrative purposes only and are not a recommendation, an offer to sell, or a solicitation of an offer to buy any security.